11 results on '"Foo, Roger"'
Search Results
2. Using "old" medications to fight new COVID-19: Re-purposing with a purpose.
- Author
-
Wang, Yibin, Foo, Roger, and Thum, Thomas
- Subjects
- *
COVID-19 , *DRUGS , *ACE inhibitors , *COVID-19 pandemic , *NEPRILYSIN - Published
- 2020
- Full Text
- View/download PDF
3. Cardiovascular molecular mechanisms of disease with COVID-19.
- Author
-
Foo, Roger, Wang, Yibin, Zimmermann, Wolfram-Hubertus, Backs, Johannes, and Wang, Dao Wen
- Subjects
- *
COVID-19 - Published
- 2020
- Full Text
- View/download PDF
4. Dimethyl sulfoxide (DMSO) enhances direct cardiac reprogramming by inhibiting the bromodomain of coactivators CBP/p300.
- Author
-
Lim, Choon Kiat, Efthymios, Motakis, Tan, Wilson, Autio, Matias Ilmari, Tiang, Zenia, Li, Peter Yiqing, and Foo, Roger Sik Yin
- Subjects
- *
DIMETHYL sulfoxide , *DRUG target , *SMALL molecules , *FIBROBLASTS , *TRANSCRIPTOMES , *MYOCARDIAL infarction , *HEART - Abstract
Direct cardiac reprogramming represents an attractive way to reversing heart damage caused by myocardial infarction because it removes fibroblasts, while also generating new functional cardiomyocytes. Yet, the main hurdle for bringing this technique to the clinic is the lack of efficacy with current reprogramming protocols. Here, we describe our unexpected discovery that DMSO is capable of significantly augmenting direct cardiac reprogramming in vitro. Upon induction with cardiac transcription factors- Gata4 , Hand2 , Mef2c and Tbx5 (GHMT), the treatment of mouse embryonic fibroblasts (MEFs) with 1% DMSO induced ~5 fold increase in Myh6 -mCherry+ cells, and significantly upregulated global expression of cardiac genes, including Myh6 , Ttn , Nppa , Myh7 and Ryr2. RNA-seq confirmed upregulation of cardiac gene programmes and downregulation of extracellular matrix-related genes. Treatment of TGF-β1, DMSO, or SB431542, and the combination thereof, revealed that DMSO most likely targets a separate but parallel pathway other than TGF-β signalling. Subsequent experiments using small molecule screening revealed that DMSO enhances direct cardiac reprogramming through inhibition of the CBP/p300 bromodomain, and not its acetyltransferase property. In conclusion, our work points to a direct molecular target of DMSO, which can be used for augmenting GHMT-induced direct cardiac reprogramming and possibly other cell fate conversion processes. [Display omitted] • DMSO enhances direct reprogramming of mouse embryonic fibroblasts to cardiomyocytes. • CBP/p300 bromodomain inhibition recapitulates the enhancement effect of DMSO. • High transcriptomic concordance exists between DMSO and CBP/p300 bromodomain inhibition. • CBP/p300 HAT domain inhibition failed to enhance direct cardiac reprogramming. • Enhancement effect by DMSO is additive to TGF-β signalling inhibition. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Hypertrophic signaling compensates for contractile and metabolic consequences of DNA methyltransferase 3A loss in human cardiomyocytes.
- Author
-
Madsen, Alexandra, Krause, Julia, Höppner, Grit, Hirt, Marc N., Tan, Wilson Lek Wen, Lim, Ives, Hansen, Arne, Nikolaev, Viacheslav O., Foo, Roger S.Y., Eschenhagen, Thomas, and Stenzig, Justus
- Subjects
- *
DNA methyltransferases , *INDUCED pluripotent stem cells , *CONTRACTILE proteins , *DNA methylation , *CELL metabolism , *CARDIAC hypertrophy , *DNA - Abstract
The role of DNA methylation in cardiomyocyte physiology and cardiac disease remains a matter of controversy. We have recently provided evidence for an important role of DNMT3A in human cardiomyocyte cell homeostasis and metabolism, using engineered heart tissue (EHT) generated from human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes carrying a knockout of the de novo DNA methyltransferase DNMT3A. Unlike isogenic control EHT, knockout EHT displayed morphological abnormalities such as lipid accumulations inside cardiomyocytes associated with impaired mitochondrial metabolism, as well as functional defects and impaired glucose metabolism. Here, we analyzed the role of DNMT3A in the setting of cardiac hypertrophy. We induced hypertrophic signaling by treatment with 50 nM endothelin-1 and 20 μM phenylephrine for one week and assessed EHT contractility, morphology, DNA methylation, and gene expression. While both knockout EHTs and isogenic controls showed the expected activation of the hypertrophic gene program, knockout EHTs were protected from hypertrophy-related functional impairment. Conversely, hypertrophic treatment prevented the metabolic consequences of a loss of DNMT3A, i.e. abolished lipid accumulation in cardiomyocytes likely by partial normalization of mitochondrial metabolism and restored glucose metabolism and metabolism-related gene expression of knockout EHT. Together, these data suggest an important role of DNA methylation not only for cardiomyocyte physiology, but also in the setting of cardiac disease. [Display omitted] • Loss of DNMT3A in cardiomyocytes pathologically affects metabolism and contractility. • Loss of DNMT3A attenuates cardiomyocyte functional impairment in hypertrophy. • Hypertrophic signaling improves mitochondrial metabolism in the absence of DNMT3A. • Hypertrophic signaling rescues glucose metabolism in DNMT3A knockout cardiomyocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. What we know about cardiomyocyte dedifferentiation.
- Author
-
Zhu, Yike, Do, Vinh Dang, Richards, A. Mark, and Foo, Roger
- Subjects
- *
HEART injuries , *HEART diseases , *HEART failure , *KNOWLEDGE gap theory , *CELL division , *VERTEBRATES , *ZEBRA danio - Abstract
Cardiomyocytes (CMs) lost during cardiac injury and heart failure (HF) cannot be replaced due to their limited proliferative capacity. Regenerating the failing heart by promoting CM cell-cycle re-entry is an ambitious solution, currently vigorously pursued. Some genes have been proven to promote endogenous CM proliferation, believed to be preceded by CM dedifferentiation, wherein terminally differentiated CMs are initially reversed back to the less mature state which precedes cell division. However, very little else is known about CM dedifferentiation which remains poorly defined. We lack robust molecular markers and proper understanding of the mechanisms driving dedifferentiation. Even the term dedifferentiation is debated because there is no objective evidence of pluripotency, and could rather reflect CM plasticity instead. Nonetheless, the significance of CM transition states on cardiac function, and whether they necessarily lead to CM proliferation, remains unclear. This review summarises the current state of knowledge of both natural and experimentally induced CM dedifferentiation in non-mammalian vertebrates (primarily the zebrafish) and mammals, as well as the phenotypes and molecular mechanisms involved. The significance and potential challenges of studying CM dedifferentiation are also discussed. In summary, CM dedifferentiation, essential for CM plasticity, may have an important role in heart regeneration, thereby contributing to the prevention and treatment of heart disease. More attention is needed in this field to overcome the technical limitations and knowledge gaps. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes.
- Author
-
Lu, Dongchao, Chatterjee, Shambhabi, Xiao, Ke, Riedel, Isabelle, Wang, Yibin, Foo, Roger, Bär, Christian, and Thum, Thomas
- Subjects
- *
COVID-19 , *SARS-CoV-2 , *MICRORNA , *ANGIOTENSIN converting enzyme , *MESSENGER RNA , *MIDDLE East respiratory syndrome - Abstract
The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million cases were reported by 24th July 2020. Angiotensin-converting enzyme 2 (ACE2) is a COVID-19 entry receptor regulating host cell infection. A recent study reported that ACE2 is expressed in cardiomyocytes. In this study, we aimed to explore if there are microRNA (miRNA) molecules which target ACE2 and which may be exploited to regulate the SARS-CoV-2 receptor. Our data reveal that both Ace2 mRNA and Ace2 protein levels are inhibited by miR-200c in rat primary cardiomyocytes and importantly, in human iPSC-derived cardiomyocytes. We report the first miRNA candidate that can target ACE2 in cardiomyocytes and thus may be exploited as a preventive strategy to treat cardiovascular complications of COVID-19. • ACE2 is expressed in various cardiovascular cells including cardiomyocytes. • MicroRNA molecules can play an important role in ACE2 regulation. • MiR-200c can modulate ACE2 expression in both rat and human cardiomyocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Pharmacological inhibition of DNA methylation attenuates pressure overload-induced cardiac hypertrophy in rats.
- Author
-
Stenzig, Justus, Schneeberger, Yvonne, Löser, Alexandra, Peters, Barbara S., Schaefer, Andreas, Zhao, Rong-Rong, Ng, Shi Ling, Höppner, Grit, Geertz, Birgit, Hirt, Marc N., Tan, Wilson, Wong, Eleanor, Reichenspurner, Hermann, Foo, Roger S.-Y., and Eschenhagen, Thomas
- Subjects
- *
LABORATORY rats , *DNA methylation , *CARDIAC hypertrophy , *METHYLTRANSFERASES , *HEART cells - Abstract
Background Heart failure is associated with altered gene expression and DNA methylation. De novo DNA methylation is associated with gene silencing, but its role in cardiac pathology remains incompletely understood. We hypothesized that inhibition of DNA methyltransferases (DNMT) might prevent the deregulation of gene expression and the deterioration of cardiac function under pressure overload (PO). To test this hypothesis, we evaluated a DNMT inhibitor in PO in rats and analysed DNA methylation in cardiomyocytes. Methods and results Young male Wistar rats were subjected to PO by transverse aortic constriction (TAC) or to sham surgery. Rats from both groups received solvent or 12.5 mg/kg body weight of the non-nucleosidic DNMT inhibitor RG108, initiated on the day of the intervention. After 4 weeks, we analysed cardiac function by MRI, fibrosis with Sirius Red staining, gene expression by RNA sequencing and qPCR, and DNA methylation by reduced representation bisulphite sequencing (RRBS). RG108 attenuated the ~70% increase in heart weight/body weight ratio of TAC over sham to 47% over sham, partially rescued reduced contractility, diminished the fibrotic response and the downregulation of a set of genes including Atp2a2 (SERCA2a) and Adrb1 (beta1-adrenoceptor). RG108 was associated with significantly lower global DNA methylation in cardiomyocytes by ~2%. The differentially methylated pathways were “cardiac hypertrophy”, “cell death” and “xenobiotic metabolism signalling”. Among these, “cardiac hypertrophy” was associated with significant methylation differences in the group comparison sham vs. TAC, but not significant between sham+RG108 and TAC+RG108 treatment, suggesting that RG108 partially prevented differential methylation. However, when comparing TAC and TAC+RG108, the pathway cardiac hypertrophy was not significantly differentially methylated. Conclusions DNMT inhibitor treatment is associated with attenuation of cardiac hypertrophy and moderate changes in cardiomyocyte DNA methylation. The potential mechanistic link between these two effects and the role of non-myocytes need further clarification. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Natriuretic peptide receptor 3 (NPR3) is regulated by microRNA-100.
- Author
-
Wong, Lee Lee, Wee, Abby S.Y., Lim, Jia Yuen, Ng, Jessica Y.X., Chong, Jenny P.C., Liew, Oi Wah, Lilyanna, Shera, Martinez, Eliana C., Ackers-Johnson, Matthew Andrew, Vardy, Leah A., Armugam, Arunmozhiarasi, Jeyaseelan, Kandiah, Ng, Tze P., Lam, Carolyn S.P., Foo, Roger S.Y., Richards, Arthur Mark, and Chen, Yei-Tsung
- Subjects
- *
HEART failure treatment , *NATRIURETIC peptide receptors , *MICRORNA , *HOMEOSTASIS , *GENE expression , *MESSENGER RNA - Abstract
Natriuretic peptide receptor 3 (NPR3) is the clearance receptor for the cardiac natriuretic peptides (NPs). By modulating the level of NPs, NPR3 plays an important role in cardiovascular homeostasis. Although the physiological functions of NPR3 have been explored, little is known about its regulation in health or disease. MicroRNAs play an essential role in the post-transcriptional expression of many genes. Our aim was to investigate potential microRNA-based regulation of NPR3 in multiple models. Hypoxic challenge elevated levels of NPPB and ADM mRNA, as well as NT-proBNP and MR-proADM in human left ventricle derived cardiac cells (HCMa), and in the corresponding conditioned medium, as revealed by qRT-PCR and ELISA. NPR3 was decreased while NPR1 was increased by hypoxia at mRNA and protein levels in HCMa. Down-regulation of NPR3 mRNA was also observed in infarct and peri-infarct cardiac tissue from rats undergoing myocardial infarction. From microRNA microarray analyses and microRNA target predictive databases, miR-100 was selected as a candidate regulator of NPR3 expression. Further analyses confirmed up-regulation of miR-100 in hypoxic cells and associated conditioned media. Antagomir-based silencing of miR-100 enhanced NPR3 expression in HCMa. Furthermore, miR-100 levels were markedly up-regulated in rat hearts and in peripheral blood after myocardial infarction and in the blood from heart failure patients. Results from this study point to a role for miR-100 in the regulation of NPR3 expression, and suggest a possible therapeutic target for modulation of NP bioactivity in heart disease. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. DNA methyl transferase 3A loss in human engineered heart tissue induces distinct alterations of contractility.
- Author
-
Stenzig, Justus, Löser, Alexandra, Krause, Julia, Hansen, Arne, Höppner, Grit, Foo, Roger, and Eschenhagen, Thomas
- Subjects
- *
DNA , *INDUCED pluripotent stem cells - Published
- 2020
- Full Text
- View/download PDF
11. Cardiac epigenetics: Driving signals to the cardiac epigenome in development and disease.
- Author
-
Robinson, Emma Louise, Anene-Nzelu, Chukwuemeka George, Rosa-Garrido, Manuel, and Foo, Roger S.Y.
- Subjects
- *
EPIGENOMICS , *EPIGENETICS , *HISTONES , *CELL determination , *LINCRNA , *CARDIOVASCULAR system , *CYTOLOGY , *CARDIAC regeneration - Abstract
Conrad Waddington's famous illustration of a ball poised at the top of an undulating epigenetic landscape is often evoked when one thinks of epigenetics. Although the original figure was a metaphor for gene regulation during cell fate determination, we now know that epigenetic regulation is important for the homeostasis of every tissue and organ in the body. This is evident in the cardiovascular system, one of the first organs to develop and one whose function is vital to human life. Epigenetic mechanisms are central in regulating transcription and signaling programs that drive cardiovascular disease and development. The epigenome not only instructs cell and context specific gene expression signatures, but also retains "memory" of past events and can pass it down to subsequent generations. Understanding the various input and output signals from the cardiac epigenome is crucial for unraveling the molecular underpinnings of cardiovascular disease and development. This knowledge is useful for patient risk stratification, understanding disease pathophysiology, and identifying novel approaches for cardiac regeneration and therapy. In this special issue, a series of high-quality reviews and original research articles examining the field of cardiac epigenetics will broaden our insights into this fundamental aspect of molecular and cellular cardiology. Topics include DNA methylation, histone modifications, chromatin architecture, transcription factors, and long non-coding RNA biology in the diverse cell types that comprise the cardiovascular system. We hope that our readers will expand their horizons and be challenged to envision innovative strategies to further probe the epigenome and develop diagnostic and therapeutic solutions for cardiovascular pathologies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.